US EditionPfizer stock jumps nearly 4% — what’s driving PFE after the obesity-drug data drop
2 Articles
2 Articles
News-Washington has announced positive results in advanced clinical trials of PF'3944, designed to be given to the patient only once a month. The Vesper-3 study data in the second phase of the tests, which included 312 participants suffering from obesity or overweight, showed that the PF'3944 drug obtained by Pf'3944 through its acquisition of Metsira Biotechnology late last year contributed to the loss of up to 12.3% of total body weight after …
Pfizer stock jumps nearly 4% — what’s driving PFE after the obesity-drug data drop
New York, February 4, 2026, 19:44 EST — After-hours Pfizer Inc shares gained 3.9%, closing at $26.78 on Wednesday, then held steady in after-hours trading. The move capped a volatile two days driven by fresh obesity drug data and quarterly earnings. (Reuters) Pfizer’s move is crucial as the company tries to reset expectations following a post-pandemic slump and faces a wave of products nearing exclusivity loss—when patents or regulatory barriers…
Coverage Details
Bias Distribution
- 100% of the sources lean Left
Factuality
To view factuality data please Upgrade to Premium
